Kohjin Bio Co., Ltd. Logo

Kohjin Bio Co., Ltd.

A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.

177A | T

Overview

Corporate Details

ISIN(s):
JP3283630006
LEI:
Country:
Japan
Address:
坂戸市千代田5−1−3
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kohjin Bio Co., Ltd. is a biotechnology company specializing in the development, manufacture, and sale of products for life sciences research and clinical applications. Its core offerings include tissue and cell culture media, media for microbial testing, and in-vitro diagnostic reagents. The company also provides animal-derived biological materials such as blood and serum. A key area of focus is regenerative medicine and cell therapy, where Kohjin Bio operates as a leading Contract Development and Manufacturing Organization (CDMO) in Japan, producing specialized culture media. Additionally, the company offers bioservices, including immunology contracts and the processing of cells for cancer immune therapies through partnerships with medical institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:30
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-13 07:30
Interim Report
半期報告書-第45期(2025/04/01-2026/03/31)
Japanese 215.4 KB
2025-06-27 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2025-06-24 09:09
Governance Information
内部統制報告書-第44期(2024/04/01-2025/03/31)
Japanese 25.0 KB
2025-06-24 09:08
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 09:06
Annual Report
有価証券報告書-第44期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2024-11-14 07:30
Regulatory News Service
確認書
Japanese 8.9 KB
2024-11-14 07:30
Interim Report
半期報告書-第44期(2024/04/01-2025/03/31)
Japanese 200.4 KB
2024-07-04 02:15
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2024-06-28 08:09
Registration Form
確認書
Japanese 9.0 KB
2024-06-28 08:00
Annual Report
有価証券報告書-第43期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-04-25 05:44
Major Shareholding Notification
臨時報告書
Japanese 21.2 KB
2024-04-16 08:01
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-04-08 03:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-03-22 07:00
Registration Form
有価証券届出書(新規公開時)
Japanese 3.5 MB

Automate Your Workflow. Get a real-time feed of all Kohjin Bio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kohjin Bio Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kohjin Bio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea
311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea
063160
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America
CMND
Clearside Biomedical, Inc. Logo
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America
CLSD
Clene Inc. Logo
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America
CLNN
Climb Bio, Inc. Logo
Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.
United States of America
CLYM
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea
058820
Cocrystal Pharma, Inc. Logo
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
United States of America
COCP
Co-Diagnostics, Inc. Logo
Develops patented PCR solutions for accurate infectious disease diagnostics.
United States of America
CODX

Talk to a Data Expert

Have a question? We'll get back to you promptly.